Cargando…

Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme

BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive form of brain cancer which is associated with poor prognosis. A variety of oncolytic viruses have previously shown positive efficacy against GBM, potentially offering new treatment options for patients. One such oncolytic virus is Myxoma vir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burton, Chase, Das, Arabinda, McDonald, Daniel, Vandergrift, William A, Patel, Sunil J, Cachia, David, Bartee, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251439/ https://www.ncbi.nlm.nih.gov/pubmed/30538967 http://dx.doi.org/10.2147/OV.S179335

Ejemplares similares

Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
por: Burton, Chase, et al.
Publicado: (2019)

Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019)

TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
por: Valenzuela-Cardenas, Miriam, et al.
Publicado: (2022)

Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
por: Bartee, Eric, et al.
Publicado: (2016)

Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
por: Dryja, Parker, et al.
Publicado: (2023)

Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection
por: Thomas, Raquela J., et al.
Publicado: (2023)

Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy
por: Flores, Erica B., et al.
Publicado: (2020)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series
por: Gesundheit, Benjamin, et al.
Publicado: (2020)

Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma
por: Das, Arabinda, et al.
Publicado: (2015)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

Potential of oncolytic viruses in the treatment of multiple myeloma
por: Bartee, Eric
Publicado: (2018)

The use of oncolytic virotherapy in the neoadjuvant setting
por: Thomas, Raquela J, et al.
Publicado: (2022)

Standards of care and novel approaches in the management of glioblastoma multiforme
por: Hottinger, Andreas F., et al.
Publicado: (2014)

Metabolic signatures associated with oncolytic myxoma viral infections
por: Mahar, Rohit, et al.
Publicado: (2022)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme
por: Abbruzzese, Claudia, et al.
Publicado: (2017)

Glioblastoma Multiforme: Novel Therapeutic Approaches
por: Fialho, Arsenio M., et al.
Publicado: (2012)

Glioblastoma Multiforme Masquerading as Stroke
por: Remley, William, et al.
Publicado: (2021)

Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
por: MacNeill, Amy L., et al.
Publicado: (2018)

The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells
por: Matteoni, Silvia, et al.
Publicado: (2019)

Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myeloma
por: Dunlap, Katherine M, et al.
Publicado: (2015)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Network Signatures of Survival in Glioblastoma Multiforme
por: Patel, Vishal N., et al.
Publicado: (2013)

Current Studies of Immunotherapy on Glioblastoma
por: Agrawal, Neena Stephanie, et al.
Publicado: (2014)

Tectal plate glioblastoma multiforme
por: Nemer, Michael D., et al.
Publicado: (2011)

Bilateral cystic glioblastoma multiforme
por: Kumar, Sushil, et al.
Publicado: (2013)

Glioblastoma Multiforme Stem Cells
por: Dimov, Irena, et al.
Publicado: (2011)

Atypical Presentation of Glioblastoma Multiforme
por: Al-Janabi, Wissam, et al.
Publicado: (2018)

Nanotechnology for Treatment of Glioblastoma Multiforme
por: Michael, Justin S., et al.
Publicado: (2018)

The complement system in glioblastoma multiforme
por: Bouwens van der Vlis, T. A. M., et al.
Publicado: (2018)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Survival Analysis of Glioblastoma Multiforme
por: Witthayanuwat, Supapan, et al.
Publicado: (2018)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Targeted Nanotechnology in Glioblastoma Multiforme
por: Glaser, Talita, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c4pgeeev60r0o3hev1hhadq837